Vertex Pharmaceuticals Inc (VRTX) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $4.73 (est. $4.63) — inline Revenue: $3.33B (est. $3.21B) — inline Reported: 2026-08-03 Recent Quarters Q1 FY26 (2026-05-04): EPS $4.47 vs est $4.18 · Rev $2.99B vs est $2.99B Q4 FY25 (2026-02-12): EPS $5.03 vs est $4.85 · Rev $3.19B vs est $3.17B Q3 FY25 (2025-11-03): EPS $4.80 vs est $4.35 · Rev $3.08B vs est $3.05B Q2 FY25 (2025-08-04): EPS $4.52 vs est $4.05 · Rev $2.96B vs est $2.90B About Vertex Pharmaceuticals Inc Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain ...